"Intermittent Inhibition of BRAF plus MEK Is Not Beneficial in Melanoma."

LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Compared with standard continuous dosing, intermittent dosing did not improve patient outcomes. Click to show full abstract

Compared with standard continuous dosing, intermittent dosing did not improve patient outcomes.

Keywords: beneficial melanoma; plus mek; intermittent inhibition; braf plus; mek beneficial; inhibition braf

Journal Title: Cancer discovery
Year Published: 2020

Link to full text (if available)

Share on Social Media: Sign Up to like & get
recommendations!
1

LAUSR

You are not signed in:

Sign Up!

Related content

More Information News Social Media Video Recommended